10/618,016

=> file caplus
FILE 'CAPLUS' ENTERED AT 12:50:44 ON 26 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 26 Sep 2005 VOL 143 ISS 14
FILE LAST UPDATED: 25 Sep 2005 (20050925/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d que
L1 STR



Structure attributes must be viewed using STN Express query preparation.
L3 179 SEA FILE=REGISTRY SSS FUL L1
L4 12 SEA FILE=CAPLUS L3

=> d l4 1-12 ibib abs hitstr

L4 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:470256 CAPLUS
DOCUMENT NUMBER: 143:20052
TITLE: Urea derivatives as kinase modulators
INVENTOR(S): Milanov, Zdravko V.; Patel, Hitesh K.; Grotzfeld, Robert M.; Mehta, Shamal A.; Andiliy, Lai G.; Lockhart, David J.
PATENT ASSIGNEE(S): Ambit Biosciences Corporation, USA
SOURCE: PCT Int. Appl., 350 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005048948	A2	20050602	WO 2004-US38288	20041115

WO 2005048948	A3	20050728			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 2005148605	A1	20050707	US 2004-989745		20041115
US 2005165031	A1	20050728	US 2004-989814		20041115
US 2005165024	A1	20050728	US 2004-989824		20041115
US 2005165074	A1	20050728	US 2004-990007		20041115
US 2005171171	A1	20050804	US 2004-989766		20041115
US 2005171172	A1	20050804	US 2004-989823		20041115
US 2005192314	A1	20050901	US 2004-990195		20041115
US 2005197371	A1	20050908	US 2004-990194		20041115
PRIORITY APPLN. INFO.:			US 2003-520273P	P	20031113
			US 2003-527094P	P	20031203
			US 2003-531082P	P	20031218
			US 2003-531243P	P	20031218

OTHER SOURCE(S): MARPAT 143:20052

AB The invention provides methods and compns. for treating conditions mediated by various kinases wherein derivs. of urea compds. are employed. The invention also provides methods of using the compds. and/or compns. in the treatment of a variety of diseases and unwanted conditions in subjects such as cellular proliferative disorders.

IT **852670-15-6**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(urea derivs. as kinase modulators for treatment of cellular proliferative disorders)

RN 852670-15-6 CAPLUS

CN 4-Piperidinecarboxamide, 1-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]-N-[4-[[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:	2005:325703 CAPLUS
DOCUMENT NUMBER:	142:392293
TITLE:	Preparation of heteroaryl carboxamides as analgesics.
INVENTOR(S):	Zheng, Guo Zhu; Brown, Brian S.; Turner, Sean C.; White, Tammie K.; Schmidt, Robert G.; Koenig, John R.; Lee, Chih-Hung
PATENT ASSIGNEE(S):	USA
SOURCE:	U.S. Pat. Appl. Publ., 45 pp. CODEN: USXXCO
DOCUMENT TYPE:	Patent
LANGUAGE:	English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2005080095	A1	20050414	US 2004-887383		20040708
PRIORITY APPLN. INFO.:			US 2003-486548P	P	20030711
OTHER SOURCE(S):	MARPAT 142:392293				

GI



I

AB Title compds. e.g. [I; A = specified (substituted) azinyl, azolyl; L = (dehydro)piperidinyl, (di)azabicyclooctyl; R6, R8 = H, alkenyl, alkoxy, alkyl, alkylthio, alkynyl, haloalkoxy, haloalkyl, haloalkylthio, halo, OH, SH, amino; R7 = H, alkenyl, alkoxy, alkoxycarbonyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkoxycarbonylalkyl, alkylsulfonyl, alkylthio, cycloalkoxy, cycloalkylthio, haloalkoxy, haloalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, OH, amino, etc.], were prepared Thus, 1,2,3,6-tetrahydro-4-pyridinecarboxylic acid (preparation given) was heated with 2-bromo-3-chloropyridine and K2CO3 in Me2SO overnight at 90°; the residue in CH2Cl2 at -78° was treated with CF3CO2H followed by warming to room temperature to give 3'-chloro-3,6-dihydro-2H-1,2'-bipyridine-4-carboxylic acid (uncharacterized). This was stirred overnight with 4-tert-butylaniline and EDCI in CH2Cl2 to give N-(4-tert-butylphenyl)-3'-chloro-3,6-dihydro-2H-1,2'-bipyridine-4-carboxamide. Title compds. antagonized vanilloid VR1 receptors with IC50 = 0.5-2200 nM.

IT **850039-72-4P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(claimed compound; preparation of heteroaryl carboxamides as analgesics)

RN 850039-72-4 CAPLUS

CN [1(2H),2'-Bipyridine]-4-carboxamide, N-[4-(8-azabicyclo[3.2.1]oct-8-yl)-3,5-difluorophenyl]-3,6-dihydro-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



IT **801305-52-2P 801305-90-8P 801305-91-9P**
801305-92-0P 801305-97-5P 801305-98-6P
801305-99-7P 801306-00-3P 801306-02-5P
801306-05-8P 801306-07-0P 801306-09-2P
801306-11-6P 801306-12-7P 824981-93-3P

824981-94-4P 824981-95-5P 824981-96-6P
824981-98-8P 824982-01-6P 824982-03-8P
824982-04-9P 824982-05-0P 824982-06-1P
824982-10-7P 824982-34-5P 824982-36-7P
824982-37-8P 824982-39-0P 824982-40-3P
824982-41-4P 850039-31-5P 850039-32-6P
850039-33-7P 850039-34-8P 850039-35-9P
850039-36-0P 850039-37-1P 850039-38-2P
850039-39-3P 850039-40-6P 850039-41-7P
850039-42-8P 850039-43-9P 850039-44-0P
850039-45-1P 850039-46-2P 850039-47-3P
850039-48-4P 850039-49-5P 850039-50-8P
850039-51-9P 850039-52-0P 850039-53-1P
850039-54-2P 850039-55-3P 850039-56-4P
850039-57-5P 850039-58-6P 850039-59-7P
850039-60-0P 850039-61-1P 850039-62-2P
850039-63-3P 850039-64-4P 850039-65-5P
850039-66-6P 850039-67-7P 850039-68-8P
850039-69-9P 850039-70-2P 850039-71-3P
850039-73-5P 850039-90-6P 850039-91-7P
850039-92-8P 850039-93-9P 850039-94-0P
850039-95-1P 850039-96-2P 850039-97-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of heteroaryl carboxamides as analgesics)

RN 801305-52-2 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-[4-(1,1-dimethylethyl)phenyl]-3,6-dihydro-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 801305-90-8 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-(3,4-difluorophenyl)-3,6-dihydro-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 801305-91-9 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-(4-chloro-3-fluorophenyl)-3,6-dihydro-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 801305-92-0 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3,6-dihydro-3'-(trifluoromethyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 801305-97-5 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-(4-chlorophenyl)-3,6-dihydro-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 801305-98-6 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-(3-fluoro-4-methylphenyl)-3,6-dihydro-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 801305-99-7 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-[4-(1,1-dimethylethyl)phenyl]-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 801306-00-3 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-3,6-dihydro-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 801306-02-5 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-(4-bromophenyl)-3'-chloro-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 801306-05-8 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-(4-chlorophenyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 801306-07-0 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-3,6-dihydro-N-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)



RN 801306-09-2 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-(4-ethylphenyl)-3,6-

dihydro- (9CI) (CA INDEX NAME)



RN 801306-11-6 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-(3,4-dimethylphenyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 801306-12-7 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-(3-fluoro-4-methylphenyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 824981-93-3 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-3,6-dihydro-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 824981-94-4 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-3,6-dihydro-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 824981-95-5 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-(4-fluorophenyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 824981-96-6 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-3,6-dihydro-N-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 824981-98-8 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-3,6-dihydro-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 824982-01-6 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-3,6-dihydro-N-(4-propoxyphenyl)- (9CI) (CA INDEX NAME)



RN 824982-03-8 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-[4-(dimethylamino)phenyl]-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 824982-04-9 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-[4-(diethylamino)phenyl]-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 824982-05-0 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-3,6-dihydro-N-[4-(1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 824982-06-1 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-3,6-dihydro-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 824982-10-7 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-[4-(hexahydro-1H-azepin-1-yl)phenyl]-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 824982-34-5 CAPLUS
CN 4-Piperidinecarboxamide, 1-(3-chloro-2-pyridinyl)-N-[4-(1,1-

dimethylethyl)phenyl]-3-hydroxy-, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 824982-36-7 CAPLUS
CN 4-Piperidinecarboxamide, 1-(3-chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-3-hydroxy-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 824982-37-8 CAPLUS
CN 4-Piperidinecarboxamide, 1-(3-chloro-2-pyridinyl)-4-hydroxy-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 824982-39-0 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3,6-dihydro-N-[4-(trifluoromethoxy)phenyl]-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 824982-40-3 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3,6-dihydro-3'-(trifluoromethyl)-N-[4-[(trifluoromethyl)thio]phenyl]- (9CI) (CA INDEX NAME)



RN 824982-41-4 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3,6-dihydro-3'-(trifluoromethyl)-N-[4-[(trifluoromethyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 850039-31-5 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-(4-bromo-3-fluorophenyl)-3'-chloro-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 850039-32-6 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-(4-bromo-3-methylphenyl)-3'-chloro-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 850039-33-7 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-(4-bromo-3-chlorophenyl)-3'-chloro-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 850039-34-8 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-[4-bromo-3-(trifluoromethyl)phenyl]-3'-chloro-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 850039-35-9 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-(4-chloro-3-fluorophenyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 850039-36-0 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-(3,4-dichlorophenyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 850039-37-1 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-(4-chloro-3-methylphenyl)-

3,6-dihydro- (9CI) (CA INDEX NAME)



RN 850039-38-2 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-[4-chloro-3-(trifluoromethyl)phenyl]-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 850039-39-3 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-[4-(difluoromethoxy)phenyl]-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 850039-40-6 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3-chloro-3,6-dihydro-N-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 850039-41-7 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-(3-chloro-4-methylphenyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 850039-42-8 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-(3-bromo-4-methylphenyl)-3'-chloro-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 850039-43-9 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-3,6-dihydro-N-[4-methyl-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 850039-44-0 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-3,6-dihydro-N-[4-[(trifluoromethyl)thio]phenyl]- (9CI) (CA INDEX NAME)



RN 850039-45-1 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-[3-fluoro-4-(trifluoromethyl)phenyl]-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 850039-46-2 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-[4-(1,1-dimethylethyl)-3-fluorophenyl]-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 850039-47-3 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-[4-(1,1-dimethylethyl)-3-fluorophenyl]-3,6-dihydro-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 850039-48-4 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3,6-dihydro-N-[4-(1-hydroxy-1-methylethyl)phenyl]-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 850039-49-5 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-[4-[ethyl(1-methylethyl)amino]phenyl]-3,6-dihydro-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 850039-50-8 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-(4-cyclopropylphenyl)-3,6-

dihydro- (9CI) (CA INDEX NAME)



RN 850039-51-9 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-3,6-dihydro-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 850039-52-0 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-[4-(2,2-dichloro-1-methylcyclopropyl)phenyl]-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 850039-53-1 CAPLUS
CN Benzeneacetic acid, 4-[[[3,6-dihydro-3'-(trifluoromethyl)[1(2H),2'-bipyridin]-4-yl]carbonyl]amino]-α,α-dimethyl-, methyl ester (9CI) (CA INDEX NAME)



RN 850039-54-2 CAPLUS

CN [1(2H),2'-Bipyridine]-4-carboxamide, 3,6-dihydro-N-[4-(2-hydroxy-1,1-dimethylethyl)phenyl]-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 850039-55-3 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-(4-acetylphenyl)-3,6-dihydro-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 850039-56-4 CAPLUS
CN Benzoic acid, 4-[[[3,6-dihydro-3'-(trifluoromethyl)[1(2H),2'-bipyridin]-4-yl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 850039-57-5 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-[4-[(1,1-dimethylethyl)thio]phenyl]-3,6-dihydro-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 850039-58-6 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-[4-[(1,1-

dimethylethyl)sulfonyl]phenyl]-3,6-dihydro-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 850039-59-7 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-3,6-dihydro-N-[4-[(trifluoromethyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 850039-60-0 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-[4-(1-cyano-1-methylethyl)phenyl]-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 850039-61-1 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-[4-(1-cyano-1-methylethyl)phenyl]-3,6-dihydro-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 850039-62-2 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-[3-chloro-4-

[(trifluoromethyl)thio]phenyl]-3,6-dihydro-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 850039-63-3 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-[4-[(dimethylamino)sulfonyl]phenyl]-3,6-dihydro-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 850039-64-4 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3,6-dihydro-N-[4-(1-piperidinylsulfonyl)phenyl]-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 850039-65-5 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-3,6-dihydro-N-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 850039-66-6 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-[(dimethylamino)sulfonyl]-N-[4-(1,1-dimethylethyl)phenyl]-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 850039-67-7 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-(4-chlorophenyl)-3'-[(dimethylamino)sulfonyl]-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 850039-68-8 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-[(dimethylamino)sulfonyl]-3,6-dihydro-N-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 850039-69-9 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-[4-(hexahydro-1H-azepin-1-yl)phenyl]-3,6-dihydro-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 850039-70-2 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-[4-(8-azabicyclo[3.2.1]oct-8-yl)phenyl]-3,6-dihydro-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 850039-71-3 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-[4-(8-azabicyclo[3.2.1]oct-8-yl)-3-fluorophenyl]-3,6-dihydro-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 850039-73-5 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-[4-(8-azabicyclo[3.2.1]oct-8-yl)-3,5-difluorophenyl]-3'-chloro-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 850039-90-6 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-(4-bromo-2-chlorophenyl)-3'-chloro-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 850039-91-7 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-(4-bromo-2-fluorophenyl)-3'-chloro-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 850039-92-8 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-(4-bromo-2-methylphenyl)-3'-chloro-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 850039-93-9 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-(2-fluoro-4-iodophenyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 850039-94-0 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-[4-chloro-2-(trifluoromethyl)phenyl]-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 850039-95-1 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-[2-chloro-4-(1,1-dimethylethyl)phenyl]-3,6-dihydro-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 850039-96-2 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-[4-(1,1-dimethylethyl)-2-fluorophenyl]-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 850039-97-3 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-(4-chloro-2-fluorophenyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



IT **824981-97-7P 824981-99-9P 824982-00-5P**
824982-02-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of heteroaryl carboxamides as analgesics)
RN 824981-97-7 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-3,6-dihydro-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 824981-99-9 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-[3-(1,1-dimethylethyl)phenyl]-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 824982-00-5 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-[1,1'-biphenyl]-4-yl-3'-chloro-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 824982-02-7 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-(3-fluorophenyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



IT 850040-21-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heteroaryl carboxamides as analgesics)
RN 850040-21-0 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-3,6-dihydro-N-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:158662 CAPLUS
DOCUMENT NUMBER: 142:240327
TITLE: Preparation of piperidinecarboxamide and cyclohexanecarboxamide derivatives as vanilloid receptor modulators
INVENTOR(S): Jamieson, Craig; Miller, David Drysdale; Rami, Harshad

Kantilal; Thompson, Mervyn
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016915	A1	20050224	WO 2004-EP9078	20040812

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2003-19150 A 20030814
OTHER SOURCE(S): MARPAT 142:240327
GI



I

AB The title compds. I [ring P = Ph, etc.; ring P' = Ph, pyridinyl, etc.; R1, R2 = alkyl, etc.; m = 0 or 1; n = 0 - 5; X = N, CH; a proviso is given] are prepared Thus, treatment of 4-(4-chlorophenyl)cyclohexanecarboxylic acid with thionyl chloride in N,N-dimethylacetamide, followed by reaction with 5-aminoquinoline in N,N-dimethylacetamide in the presence of diisopropylethylamine, gave 4-(4-chlorophenyl)-N-5-quinolinylcyclohexanecarboxamide. In an in vitro assay for vanilloid receptor VR1 antagonist activity, compds. of this invention showed pKb values > 7. (The pKb values were generated from the IC50 values using the Cheng-Prusoff equation.).

IT **845645-28-5P 845645-33-2P 845645-34-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperidinecarboxamide and cyclohexanecarboxamide derivs. as vanilloid receptor modulators)

RN 845645-28-5 CAPLUS

CN 4-Piperidinecarboxamide, N-[5-(aminosulfonyl)-2-methylphenyl]-1-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 845645-33-2 CAPLUS
CN 4-Piperidinecarboxamide, N-[5-(aminosulfonyl)-2-methylphenyl]-1-[5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 845645-34-3 CAPLUS
CN 4-Piperidinecarboxamide, 1-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]-N-[4-methyl-3-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:55064 CAPLUS
DOCUMENT NUMBER: 142:155821
TITLE: Preparation of substituted cyclo(hetero)alkenes for treating pain
INVENTOR(S): Kyle, Donald J.; Sun, Qun; Tafesse, Laykea
PATENT ASSIGNEE(S): Euro-Celtique, S.A., Luxembourg
SOURCE: PCT Int. Appl., 970 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005004866	A1	20050120	WO 2004-US19189	20040614

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-477744P P 20030612
OTHER SOURCE(S): MARPAT 142:155821
GI



AB The title compds. I [Ar1 = (un)substituted pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, etc.; Ar2 = (un)substituted benzothiazolyl, benzoxazolyl, benzimidazolyl, etc.; V = N, CH; X = O, S; R3 = halo, CN, OH, etc.; R4 = H, alkyl; m =0-1], compns. comprising thereof, and methods for treating or preventing, e.g., pain, UI, an ulcer, IBD, or IBS in an animal, comprising administering to an animal in need thereof an effective amount of compound I are disclosed. Several preparative examples were given to illustrate the synthesis of compds. I. E.g., a multi-step synthesis of II, starting from 2,3-dichloropyridine, was given. The compound III, an illustrative cyclo(hetero)alkene I, was tested for binding to human VR1 and showed IC50 of 148.1 nM in pH-based assay and IC50 of 4.4 nM in capsaicin-based assay.

IT **828265-94-7P 828265-95-8P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of substituted cyclo(hetero)alkenes as VR1 inhibitors for treating pain)

RN 828265-94-7 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3,6-dihydro-3'-nitro-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 828265-95-8 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-amino-3,6-dihydro-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



IT **801305-52-2P 801305-99-7P 801306-00-3P**
828265-79-8P 828265-80-1P 828265-81-2P
828265-82-3P 828265-83-4P 828265-93-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted cyclo(hetero)alkenes as VR1 inhibitors for treating pain)

RN 801305-52-2 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-[4-(1,1-dimethylethyl)phenyl]-3,6-dihydro-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 801305-99-7 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-[4-(1,1-dimethylethyl)phenyl]-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 801306-00-3 CAPLUS

CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-3,6-dihydro-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 828265-79-8 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-3,6-dihydro-3-methyl-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 828265-80-1 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-[4-(1,1-dimethylethyl)phenyl]-3,6-dihydro-3'-methyl- (9CI) (CA INDEX NAME)



RN 828265-81-2 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3,6-dihydro-3'-methyl-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 828265-82-3 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3,6-dihydro-3'-methyl-N-[4-(1-methylethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 828265-83-4 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3,6-dihydro-3'-methyl-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 828265-93-6 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-[4-(1,1-dimethylethyl)phenyl]-3,6-dihydro-3'-nitro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:36551 CAPLUS
DOCUMENT NUMBER: 142:134614
TITLE: A preparation of N-phenyl-heterocyclylcarboxylic acid amide derivatives, useful for treating pain
INVENTOR(S): Zheng, Guo Zhu; Brown, Brian S.; Turner, Sean C.; White, Tammie K.; Schmidt, Robert G.; Koenig, John R.; Lee, Chih-Hung
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 26 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005009841	A1	20050113	US 2003-618016	20030711
WO 2005007642	A2	20050127	WO 2004-US21836	20040709
WO 2005007642	A3	20050526		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-618016 A 20030711
OTHER SOURCE(S): MARPAT 142:134614

GI



I



II



III

AB The invention relates to a preparation of N-phenyl-heterocyclylcarboxylic acid amide derivs. of formula I [wherein: A is (un)substituted oxazolyl, imidazolyl, pyrimidinyl, or pyridinyl, etc.; L is a bond, piperazine-1,4-diyl derivative, or piperidine-1,4-diyl derivative, etc.; R1 and R3 are independently selected from H, alkenyl, alkoxy, alkylthio, or haloalkyl, etc.; R2 is H, alkoxy, alkenyl, alkyl, halogen, or OH, etc.], useful for treating pain. For instance, N-phenyl-heterocyclylcarboxylic acid amide derivative II (antinociceptive effect: 0.1 mg/kg < ED50 < 150 mg/kg) was prepared via amination of 2-bromo-3-chloropyridine by 1,2,3,6-tetrahydro-4-pyridinecarboxylic acid and subsequent amidation of the obtained bipyridinecarboxylic acid derivative III by 4-tert-butylaniline.

IT **801305-52-2P 801305-97-5P 801305-98-6P**
801305-99-7P 801306-00-3P 801306-02-5P
801306-05-8P 801306-07-0P 801306-09-2P
801306-12-7P 824981-93-3P 824981-94-4P
824981-95-5P 824981-96-6P 824981-97-7P
824981-98-8P 824981-99-9P 824982-00-5P
824982-01-6P 824982-02-7P 824982-03-8P
824982-04-9P 824982-05-0P 824982-06-1P
824982-10-7P 824982-34-5P 824982-36-7P
824982-37-8P 824982-39-0P 824982-40-3P

824982-41-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-phenyl-heterocyclylcarboxylic acid amide derivs. useful for treating pain)

RN 801305-52-2 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-[4-(1,1-dimethylethyl)phenyl]-3,6-dihydro-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 801305-97-5 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-(4-chlorophenyl)-3,6-dihydro-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 801305-98-6 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-(3-fluoro-4-methylphenyl)-3,6-dihydro-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 801305-99-7 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-[4-(1,1-dimethylethyl)phenyl]-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 801306-00-3 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-3,6-dihydro-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 801306-02-5 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-(4-bromophenyl)-3'-chloro-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 801306-05-8 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-(4-chlorophenyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 801306-07-0 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-3,6-dihydro-N-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)



RN 801306-09-2 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-(4-ethylphenyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 801306-12-7 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-(3-fluoro-4-methylphenyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 824981-93-3 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-3,6-dihydro-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 824981-94-4 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-3,6-dihydro-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 824981-95-5 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-(4-fluorophenyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 824981-96-6 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-3,6-dihydro-N-[4-

(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 824981-97-7 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-3,6-dihydro-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 824981-98-8 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-3,6-dihydro-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 824981-99-9 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-[3-(1,1-dimethylethyl)phenyl]-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 824982-00-5 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-[1,1'-biphenyl]-4-yl-3'-chloro-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 824982-01-6 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-3,6-dihydro-N-(4-propoxyphenyl)- (9CI) (CA INDEX NAME)



RN 824982-02-7 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-(3-fluorophenyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 824982-03-8 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-[4-(dimethylamino)phenyl]-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 824982-04-9 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-[4-(diethylamino)phenyl]-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 824982-05-0 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-3,6-dihydro-N-[4-(1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 824982-06-1 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-3,6-dihydro-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 824982-10-7 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-[4-(hexahydro-1H-azepin-1-yl)phenyl]-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 824982-34-5 CAPLUS
CN 4-Piperidinecarboxamide, 1-(3-chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-3-hydroxy-, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 824982-36-7 CAPLUS
CN 4-Piperidinecarboxamide, 1-(3-chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-3-hydroxy-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 824982-37-8 CAPLUS
CN 4-Piperidinecarboxamide, 1-(3-chloro-2-pyridinyl)-4-hydroxy-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 824982-39-0 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3,6-dihydro-N-[4-(trifluoromethoxy)phenyl]-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 824982-40-3 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3,6-dihydro-3'-(trifluoromethyl)-N-[4-[(trifluoromethyl)thio]phenyl]- (9CI) (CA INDEX NAME)



RN 824982-41-4 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3,6-dihydro-3'-(trifluoromethyl)-N-[4-[(trifluoromethyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:1037062 CAPLUS
DOCUMENT NUMBER: 142:23193
TITLE: Preparation of pyridinecarboxamide derivatives as antiinflammatory agents
INVENTOR(S): Nakagawa, Tadakiyo; Suzuki, Tamotsu; Takenaka, Kaoru; Fujita, Shinichi; Yamada, Youji; Shima, Yoichiro; Okuzumi, Tatsuya; Yoshimura, Toshihiko; Yoshida, Masanao; Murata, Masahiro
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan
SOURCE: PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004103954	A1	20041202	WO 2004-JP7221	20040520
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: JP 2003-142681 A 20030520
OTHER SOURCE(S): MARPAT 142:23193
GI



I



II

AB The title pyridinecarboxamide derivs. I [wherein ring A = cycloalkyl, aryl, or heteroaryl; X = N or (un)substituted CH; Y = (un)substituted NH, alkylene, etc.; R1- R16 = independently H, halo, CN, NO2, etc.], or pharmaceutically acceptable salts, hydrates, or solvates thereof are prepared as antiinflammatory agents and analgesics. For example, the compound II was prepared in a multi-step synthesis. II inhibited 73% and 77% pain in rat at the dose of 3 and 10 mg/kg, resp.

IT 801305-01-1P 801305-02-2P 801305-03-3P
801305-04-4P 801305-05-5P 801305-06-6P
801305-07-7P 801305-08-8P 801305-09-9P
801305-10-2P 801305-11-3P 801305-12-4P
801305-13-5P 801305-14-6P 801305-15-7P
801305-16-8P 801305-17-9P 801305-18-0P
801305-19-1P 801305-20-4P 801305-21-5P
801305-22-6P 801305-23-7P 801305-24-8P
801305-25-9P 801305-26-0P 801305-27-1P
801305-28-2P 801305-29-3P 801305-30-6P
801305-31-7P 801305-32-8P 801305-33-9P
801305-34-0P 801305-36-2P 801305-37-3P
801305-38-4P 801305-39-5P 801305-40-8P
801305-42-0P 801305-45-3P 801305-50-0P
801305-52-2P 801305-85-1P 801305-86-2P
801305-87-3P 801305-88-4P 801305-89-5P
801305-90-8P 801305-91-9P 801305-92-0P
801305-93-1P 801305-94-2P 801305-95-3P
801305-96-4P 801305-97-5P 801305-98-6P
801305-99-7P 801306-00-3P 801306-01-4P
801306-02-5P 801306-03-6P 801306-04-7P
801306-05-8P 801306-06-9P 801306-07-0P
801306-08-1P 801306-09-2P 801306-10-5P
801306-11-6P 801306-12-7P 801306-35-4P
801306-36-5P 801306-46-7P 801306-47-8P
801306-49-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyridinecarboxamide derivs. as antiinflammatory agents)



RN 801305-52-2 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-[4-(1,1-dimethylethyl)phenyl]-3,6-dihydro-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 801305-85-1 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3,6-dihydro-N-(4-methylphenyl)-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 801305-86-2 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-(4-fluorophenyl)-3,6-dihydro-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 801305-87-3 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-(4-ethenylphenyl)-3,6-dihydro-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 801305-88-4 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3,6-dihydro-N-[4-(1-methylethyl)phenyl]-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 801305-89-5 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3,6-dihydro-N-(4-iodophenyl)-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 801305-90-8 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-(3,4-difluorophenyl)-3,6-dihydro-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 801305-91-9 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-(4-chloro-3-fluorophenyl)-3,6-dihydro-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 801305-92-0 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3,6-dihydro-3'-(trifluoromethyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 801305-93-1 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3,6-dihydro-N-[4-(methylthio)phenyl]-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 801305-94-2 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3,6-dihydro-N-(3,4,5-trichlorophenyl)-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 801305-95-3 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-(3-fluoro-4-methoxyphenyl)-3,6-dihydro-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 801305-96-4 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-(4-ethylphenyl)-3,6-dihydro-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 801305-97-5 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-(4-chlorophenyl)-3,6-dihydro-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 801305-98-6 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-(3-fluoro-4-methylphenyl)-3,6-dihydro-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 801305-99-7 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-[4-(1,1-dimethylethyl)phenyl]-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 801306-00-3 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-3,6-dihydro-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 801306-01-4 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-3,6-dihydro-N-(4-iodophenyl)- (9CI) (CA INDEX NAME)



RN 801306-02-5 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-(4-bromophenyl)-3'-chloro-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 801306-03-6 CAPLUS
CN Benzoic acid, 4-[[(3'-chloro-3,6-dihydro[1(2H),2'-bipyridin]-4-yl)carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 801306-04-7 CAPLUS

CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-3,6-dihydro-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)



RN 801306-05-8 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-(4-chlorophenyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 801306-06-9 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-(4-cyanophenyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 801306-07-0 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-3,6-dihydro-N-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)



RN 801306-08-1 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-(3-fluoro-4-methoxyphenyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 801306-09-2 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-(4-ethylphenyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 801306-10-5 CAPLUS
CN Benzoic acid, 3-[[(3'-chloro-3,6-dihydro[1(2H),2'-bipyridin]-4-yl)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 801306-11-6 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-(3,4-dimethylphenyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 801306-12-7 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-(3-fluoro-4-methylphenyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 801306-35-4 CAPLUS
CN Benzeneacetic acid, 4-[[(3'-chloro-3,6-dihydro[1(2H),2'-bipyridin]-4-yl)carbonyl]amino]-α,α-dimethyl-, methyl ester (9CI) (CA INDEX NAME)



RN 801306-36-5 CAPLUS
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-3,6-dihydro-N-[4-(2-hydroxy-1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 801306-46-7 CAPLUS
CN 4-Piperidinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-1-(6-methoxy-3-nitro-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 801306-47-8 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-chloro-6-[4-[[[4-(1,1-dimethylethyl)phenyl]amino]carbonyl]-1-piperidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 801306-49-0 CAPLUS
CN 4-Piperidinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-1-(2-pyridinyl)-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:967396 CAPLUS
DOCUMENT NUMBER: 142:211395
TITLE: Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist
AUTHOR(S): Swanson, Devin M.; Dubin, Adrienne E.; Shah, Chandra; Nasser, Nadia; Chang, Leon; Dax, Scott L.; Jetter, Michele; Breitenbucher, J. Guy; Liu, Changlu; Mazur, Curt; Lord, Brian; Gonzales, Lisa; Hoey, Kenway; Rizzolio, Michele; Bogenstaetter, Michael; Codd, Ellen E.; Lee, Doo H.; Zhang, Sui-Po; Chaplan, Sandra R.; Carruthers, Nicholas I.
CORPORATE SOURCE: Johnson Johnson Pharmaceutical Research and Development L.L.C., San Diego, CA, 92121, USA
SOURCE: Journal of Medicinal Chemistry (2005), 48(6), 1857-1872
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB High throughput screening using the recombinant human TRPV1 receptor was used to identify a series of pyridinylpiperazine ureas as TRPV1 vanilloid receptor ligands. Exploration of the structure-activity relationships by parallel synthesis identified the essential pharmacophoric elements for antagonism that permitted further optimization via targeted synthesis to provide a potent orally bioavailable and selective TRPV1 modulator 41 active in several in vivo models.

IT **801305-02-2P**
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(identification and biol. evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide as high affinity TRPV1 (VR1) vanilloid receptor antagonist)

RN 801305-02-2 CAPLUS

CN 4-Piperidinecarboxamide, N-[4-(trifluoromethyl)phenyl]-1-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:696342 CAPLUS
DOCUMENT NUMBER: 141:225302
TITLE: Preparation of N-arylheterocycles as melanin concentrating hormone (MCH) antagonists.
INVENTOR(S): Schwink, Lothar; Stengelin, Siegfried; Gossel, Matthias; Boehme, Thomas; Hessler, Gerhard; Stahl, Petra; Gretzke, Dirk
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany
SOURCE: PCT Int. Appl., 390 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004072025	A2	20040826	WO 2004-EP1342	20040213
WO 2004072025	A3	20041223		
W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10306250	A1	20040909	DE 2003-10306250	20030214
US 2004220191	A1	20041104	US 2004-779853	20040217

PRIORITY APPLN. INFO.: DE 2003-10306250 A 20030214
US 2003-488545P P 20030718

OTHER SOURCE(S): MARPAT 141:225302
GI



I

AB Title compds. [I; R1, R2 = H, alkyl, alkoxyalkyl, aryloxyalkyl, alkylcarbonyl, alkenylcarbonyl, etc.; R1R2N = atoms to form a 4-10 membered mono-, bi-, or spirocyclic (substituted) ring; R3 = H, alkyl; R4, R5 = H, alkyl, OH, alkoxy, alkylcarbonyloxy, alkylthio; R6-R9 = H, alkyl; R6R7, R8R9 = O; A, B, D, G = N, CR42; AB, DG = CR42; R42 = H, F, Cl, Br, iodo, CF3, NO2, cyano, OCF3, alkoxy, alkylthio, alkenyl, cycloalkyl, cycloalkoxy, cycloalkenyl, alkynyl, CO2H, etc.; R10 = H, alkyl, alkenyl, alkynyl; X = NR52, O, bond, C:C, C.tplbond.C, etc.; R52 = H, alkyl; E = (substituted) C3-14 carbocyclyl, heterocyclyl; K = bond, O, CH2O, S, SO, CO, C:C, C.tplbond.C, etc.; R11 = H, alkyl, alkoxyalkyl, alkenyl, alkynyl, 3-10 membered (substituted) mono-, bi-, tri- or spirocyclic ring; EKR11 = (unsatd.) tricyclic ring; m, n = 0-2], were prepared Thus, N-[1-(4-aminophenyl)pyrrolidin-3-yl]piperidine was treated with carbonyldiimidazole and then with 4-(4-chlorophenyl)piperidine to give 4-(4-chlorophenyl)piperidine-1-carboxylic acid [4-[3-(acetylmethylamino)pyrrolidin-1-yl]phenyl]amide. The latter at 30 mg/kg orally in female NMRI mice reduced milk consumption by 64%.

IT **748169-70-2P 748169-74-6P 748169-77-9P 748175-39-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-arylheterocycles as MCH antagonists)

RN 748169-70-2 CAPLUS

CN 4-Piperidinecarboxamide, 1-(5-chloro-2-pyridinyl)-N-[4-[3-(dimethylamino)-1-pyrrolidinyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 748169-74-6 CAPLUS

CN 4-Piperidinecarboxamide, N-[4-[3-(dimethylamino)-1-pyrrolidinyl]phenyl]-1-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 748169-77-9 CAPLUS

CN 4-Piperidinecarboxamide, 1-(5-chloro-2-pyridinyl)-N-[4-[3-(dimethylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 748175-39-5 CAPLUS
CN 4-Piperidinecarboxamide, N-[4-[3-(dimethylamino)-1-pyrrolidinyl]phenyl]-1-[5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:354920 CAPLUS
DOCUMENT NUMBER: 140:375171
TITLE: Preparation of benzimidazoles as vanilloid receptor ligands
INVENTOR(S): Balan, Chenera; Bo, Yunxin; Dominguez, Celia; Fotsch, Christopher H.; Gore, Vijay K.; Ma, Vu Van; Norman, Mark H.; Ognyanov, Vassil I.; Qian, Yi-xin; Wang, Xianghong; Xi, Ning; Xu, Shimin
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: PCT Int. Appl., 259 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004035549	A1	20040429	WO 2003-US32823	20031016
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2501539	AA	20040429	CA 2003-2501539	20031016
US 2004152690	A1	20040805	US 2003-688246	20031016
EP 1551811	A1	20050713	EP 2003-809075	20031016
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.: US 2002-419791P P 20021017
WO 2003-US32823 W 20031016

OTHER SOURCE(S): MARPAT 140:375171
GI



I



II

AB Title compds. I [wherein B, D = independently substituted un/partially/saturated C1-C3 chain, with provisos; A, C = independently N, CH and derivs. with at least one of A and C is N; E, F, G, H = independently N, CH and derivs.; R1 = H, (CH2)mR3 and derivs.; m = 0,1 or 2; R3 = independently (un)substituted un/partially/saturated 5, 6, or 7-membered monocyclic, or 6-, 7-, 8-, 9-, 10- or 11-membered bicyclic ring containing 0-4 heteroatoms selected from N, O, and S] were prepared as vanilloid receptor ligands (no data). For example, II was prepared by alkylation of piperazine with 2-chloro-6-trifluoromethyl-1H-benzimidazole(preparation given) in DMSO and reaction with 2,6-dichlorobenzyl bromide in DMF. Tests for capsaicin agonist and antagonist properties at vanilloid receptor type 1 are given (no data). I are useful in the treatment of vanilloid-receptor-mediated diseases, such as inflammatory or neuropathic pain and diseases involving sensory nerve function such as asthma, rheumatoid arthritis, osteoarthritis, inflammatory bowel disorders, urinary incontinence, migraine and psoriasis (no data).

IT **683240-63-3P**, N-(2-Amino-4-trifluoromethylphenyl)-1-[1-(3-chloropyridin-2-yl)piperidin-4-yl]formamide **683240-64-4P**, N-(2-Amino-5-trifluoromethylphenyl)-1-[1-(3-chloropyridin-2-yl)piperidin-4-yl]formamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of benzimidazoles as vanilloid receptor ligands)

RN 683240-63-3 CAPLUS

CN 4-Piperidinecarboxamide, N-[2-amino-4-(trifluoromethyl)phenyl]-1-(3-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 683240-64-4 CAPLUS

CN 4-Piperidinecarboxamide, N-[2-amino-5-(trifluoromethyl)phenyl]-1-(3-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:591178 CAPLUS
DOCUMENT NUMBER: 139:149653
TITLE: Preparation of quinoxaline derivatives as poly(ADP-ribose) polymerase (PARP) inhibitors for treatment of rheumatoid arthritis
INVENTOR(S): Takayama, Kazuhisa; Masuda, Naoyuki; Hondo, Takeshi; Hirabayashi, Ryoji; Seki, Norio; Koga, Yuji; Naito, Ryo; Okamoto, Yoshinori; Kaizawa, Hiroyuki; Okuda, Takao; Okada, Youhei; Takeuchi, Makoto
PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062234	A1	20030731	WO 2003-JP545	20030122

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: JP 2002-14121 A 20020123
OTHER SOURCE(S): MARPAT 139:149653
GI



I



II

AB The title quinoxaline derivs. with general formula of I [wherein wherein R1 = H, alkoxy, halo, or (un)substituted alkyl; R2 = halo, (un)substituted OH, SH, or amino, etc.; R3 = H, OH, halo, (un)substituted cycloalkyl, cycloalkenyl, heterocyclyl, or alkyl, etc.; with exclusions] and pharmaceutically acceptable salts thereof are prepared as poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of rheumatoid arthritis. For example, the quinoxalinecarboxamide II was prepared in a four-step synthesis starting from N-(tert-butoxycarbonyl)isonipecotic acid comprising ring formation reaction. Some of compds. I showed IC50 of 3.8-72 nM against human PARP.

IT **569667-10-3P 569667-13-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of quinoxaline derivs. as PARP inhibitors for treatment of rheumatoid arthritis)

RN 569667-10-3 CAPLUS

CN 5-Quinoxalinecarboxamide, 3-[6-[4-[[(2-fluorophenyl)amino]carbonyl]-1-piperidinyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 569667-13-6 CAPLUS

CN 5-Quinoxalinecarboxamide, 3-[6-[4-[[(4-iodophenyl)amino]carbonyl]-1-piperidinyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:568105 CAPLUS
DOCUMENT NUMBER: 137:125170
TITLE: Preparation of anilides as microsomal triglyceride-exchanging protein (MTP) inhibitors and their use for prophylactic and therapeutic treatment of hyperlipidemia and/or arteriosclerosis
INVENTOR(S): Yokomoto, Shoji; Hirao, Yuzo; Tamura, Koichi; Inokuma, Kenichi; Akamatsu, Hisashi
PATENT ASSIGNEE(S): Wakunaga Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 18 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002212179	A2	20020731	JP 2001-5845	20010115

PRIORITY APPLN. INFO.: JP 2001-5845 20010115
OTHER SOURCE(S): MARPAT 137:125170
GI



I



AB Anilides I [R1, R2 = H, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted saturated cyclic amino, halo, etc; R3 = H, alkyl, halo; R4 = (un)substituted (cyclo)alkyl; A = N, CR6 [R6 = H; R2R6 may form di- or tricyclic condensed (hetero)cyclic ring]; B = N, CH; W = H, halo, (un)substituted (hetero)aryl, D = O, S; ring E = aromatic hydrocarbyl, aromatic heterocyclyl, unsatd. cyclohydrocarbyl; G = Q; m = 1, 2; p = 2,3; J = NH, O, S, alkylene, condensed alicyclic residue, condensed benzene residue; X = O, S, bond; Y = amino, bond, alkylene, alkenylene, (un)substituted (hetero)aryl; Z = bond, alkylene, alkenylene, (un)substituted (hetero)aryl; Y = Z ≠ bond; R5 = H, alkyl, aralkyl] are prepared Thus, N-butyl-N-(4,6-diethoxypyrimidin-5-yl)-5-bromopentanamide was treated with N-(piperidin-4-yl)-4'-trifluoromethylbiphenyl-2-carboxamide, K2CO3, and KI under reflux to give N-butyl-N-(4,6-diethoxypyrimidin-5-yl)-5-[4-(4'-trifluoromethylbiphenyl-2-carboxamido)piperidino]pentanamide, which inhibited secretion of apoB lipoprotein in human HepG2 cell with IC50 value of 0.01 nM.
IT **444200-55-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of anilides as microsomal triglyceride-exchanging protein inhibitors for treatment of hyperlipidemia and/or arteriosclerosis)

RN 444200-55-9 CAPLUS

CN 3-Pyridinecarboxamide, N-(4,6-diethoxy-5-pyrimidinyl)-N-propyl-6-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]amino]carbonyl]-1-piperidinyl]-(9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:811204 CAPLUS

DOCUMENT NUMBER: 132:49888

TITLE: Cyclic hydroxamic acids as metalloproteinase inhibitors

INVENTOR(S): Xue, Chu-Baio; Decicco, Carl P.; He, Xiaohua

PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA

SOURCE: PCT Int. Appl., 222 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9965867	A1	19991223	WO 1999-US13723	19990617
W: AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2333554	AA	19991223	CA 1999-2333554	19990617
AU 9946923	A1	20000105	AU 1999-46923	19990617
EP 1087937	A1	20010404	EP 1999-930371	19990617
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
JP 2002518368	T2	20020625	JP 2000-554694	19990617
US 6429213	B1	20020806	US 1999-335086	19990617
US 2003139597	A1	20030724	US 2002-177235	20020620
US 6858626	B2	20050222		

PRIORITY APPLN. INFO.:	US 1998-89557P	P	19980617
	US 1999-127599P	P	19990402
	US 1999-335086	A3	19990617
	WO 1999-US13723	W	19990617

OTHER SOURCE(S): MARPAT 132:49888

GI



I

AB Title cyclic hydroxamic acids were prepared which are useful as metalloprotease inhibitors (no data). Thus, trans-1,2-cyclopentanedicarboxylic acid was amidated with 4-phenylpiperidine and treated with NH2OH to give the hydroxamide I.

IT **252918-46-0P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclic hydroxamic acids as metalloproteinase inhibitors)

RN 252918-46-0 CAPLUS

CN 3,4-Piperidinedicarboxamide, N3-hydroxy-N4-[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]-1-(5-nitro-2-pyridinyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> => file uspatfull
FILE 'USPATFULL' ENTERED AT 12:51:44 ON 26 SEP 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 22 Sep 2005 (20050922/PD)
FILE LAST UPDATED: 22 Sep 2005 (20050922/ED)
HIGHEST GRANTED PATENT NUMBER: US6948186
HIGHEST APPLICATION PUBLICATION NUMBER: US2005210555
CA INDEXING IS CURRENT THROUGH 22 Sep 2005 (20050922/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 22 Sep 2005 (20050922/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2005
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2005

>>> USPAT2 is now available. USPATFULL contains full text of the <<<

>>> original, i.e., the earliest published granted patents or <<<
>>> applications. USPAT2 contains full text of the latest US <<<
>>> publications, starting in 2001, for the inventions covered in <<<
>>> USPATFULL. A USPATFULL record contains not only the original <<<
>>> published document but also a list of any subsequent <<<
>>> publications. The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d que
L1 STR



Structure attributes must be viewed using STN Express query preparation.
L3 179 SEA FILE=REGISTRY SSS FUL L1
L5 6 SEA FILE=USPATFULL L3

=> d l5 1-6 ibib abs hitstr

L5 ANSWER 1 OF 6 USPATFULL on STN
ACCESSION NUMBER: 2005:93416 USPATFULL
TITLE: Novel amides useful for treating pain
INVENTOR(S): Zheng, Guo Zhu, Lake Bluff, IL, UNITED STATES
Brown, Brian S., Evanston, IL, UNITED STATES
Turner, Sean C., Mannheim, GERMANY, FEDERAL REPUBLIC OF
White, Tammie K., Gurnee, IL, UNITED STATES
Schmidt, Robert G., Waukegan, IL, UNITED STATES
Koenig, John R., Chicago, IL, UNITED STATES
Lee, Chih-Hung, Vernon Hills, IL, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005080095	A1	20050414	
APPLICATION INFO.:	US 2004-887383	A1	20040708	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2003-486548P	20030711	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: ROBERT DEBERARDINE, ABBOTT LABORATORIES, 100 ABBOTT PARK ROAD, DEPT. 377/AP6A, ABBOTT PARK, IL, 60064-6008, US
NUMBER OF CLAIMS: 42
EXEMPLARY CLAIM: 1
LINE COUNT: 3739
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds of formula (I-VII) ##STR1## or a pharmaceutically acceptable salt or prodrug thereof, in which A, L, R.sub.6, R.sub.7 and R.sub.8 are defined herein. The present invention also relates to methods of trating pain using these compounds and pharmaceutical compositions including these compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **850039-72-4P**
(claimed compound; preparation of heteroaryl carboxamides as analgesics)
RN 850039-72-4 USPATFULL
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-[4-(8-azabicyclo[3.2.1]oct-8-yl)-3,5-difluorophenyl]-3,6-dihydro-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



IT **801305-52-2P 801305-90-8P 801305-91-9P**
801305-92-0P 801305-97-5P 801305-98-6P
801305-99-7P 801306-00-3P 801306-02-5P
801306-05-8P 801306-07-0P 801306-09-2P
801306-11-6P 801306-12-7P 824981-93-3P
824981-94-4P 824981-95-5P 824981-96-6P
824981-98-8P 824982-01-6P 824982-03-8P
824982-04-9P 824982-05-0P 824982-06-1P
824982-10-7P 824982-34-5P 824982-36-7P
824982-37-8P 824982-39-0P 824982-40-3P
824982-41-4P 850039-31-5P 850039-32-6P
850039-33-7P 850039-34-8P 850039-35-9P
850039-36-0P 850039-37-1P 850039-38-2P
850039-39-3P 850039-40-6P 850039-41-7P
850039-42-8P 850039-43-9P 850039-44-0P
850039-45-1P 850039-46-2P 850039-47-3P
850039-48-4P 850039-49-5P 850039-50-8P
850039-51-9P 850039-52-0P 850039-53-1P
850039-54-2P 850039-55-3P 850039-56-4P
850039-57-5P 850039-58-6P 850039-59-7P
850039-60-0P 850039-61-1P 850039-62-2P
850039-63-3P 850039-64-4P 850039-65-5P
850039-66-6P 850039-67-7P 850039-68-8P
850039-69-9P 850039-70-2P 850039-71-3P
850039-73-5P 850039-90-6P 850039-91-7P
850039-92-8P 850039-93-9P 850039-94-0P
850039-95-1P 850039-96-2P 850039-97-3P
(claimed compound; preparation of heteroaryl carboxamides as analgesics)
RN 801305-52-2 USPATFULL
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-[4-(1,1-dimethylethyl)phenyl]-3,6-

dihydro-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 801305-90-8 USPATFULL
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-(3,4-difluorophenyl)-3,6-dihydro-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 801305-91-9 USPATFULL
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-(4-chloro-3-fluorophenyl)-3,6-dihydro-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 801305-92-0 USPATFULL
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3,6-dihydro-3'-(trifluoromethyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 801305-97-5 USPATFULL
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-(4-chlorophenyl)-3,6-dihydro-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 801305-98-6 USPATFULL
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-(3-fluoro-4-methylphenyl)-3,6-dihydro-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 801305-99-7 USPATFULL
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-[4-(1,1-dimethylethyl)phenyl]-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 801306-00-3 USPATFULL
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-3,6-dihydro-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 801306-02-5 USPATFULL
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-(4-bromophenyl)-3'-chloro-3,6-dihydro- (9CI) (CA INDEX NAME)





RN 824982-02-7 USPATFULL
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-(3-fluorophenyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



IT 850040-21-0P
(preparation of heteroaryl carboxamides as analgesics)
RN 850040-21-0 USPATFULL
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-3,6-dihydro-N-[4-(1,1,2,2-tetrafluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 2 OF 6 USPATFULL on STN
ACCESSION NUMBER: 2005:11706 USPATFULL
TITLE: Novel amides useful for treating pain
INVENTOR(S): Zheng, Guo Zhu, Lake Bluff, IL, UNITED STATES
Brown, Brian S., Evanston, IL, UNITED STATES
Turner, Sean C., Mannheim, GERMANY, FEDERAL REPUBLIC OF
White, Tammie K., Gurnee, IL, UNITED STATES
Schmidt, Robert G., Waukegan, IL, UNITED STATES
Koenig, John R., Chicago, IL, UNITED STATES
Lee, Chih-Hung, Vernon Hills, IL, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005009841	A1	20050113	
APPLICATION INFO.:	US 2003-618016	A1	20030711	(10)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ROBERT DEBERARDINE, ABBOTT LABORATORIES, 100 ABBOTT PARK ROAD, DEPT. 377/AP6A, ABBOTT PARK, IL, 60064-6008
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
LINE COUNT: 2156
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds of formula (I) ##STR1##

that useful in treating pain.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 801305-52-2P 801305-97-5P 801305-98-6P
801305-99-7P 801306-00-3P 801306-02-5P
801306-05-8P 801306-07-0P 801306-09-2P
801306-12-7P 824981-93-3P 824981-94-4P
824981-95-5P 824981-96-6P 824981-97-7P
824981-98-8P 824981-99-9P 824982-00-5P
824982-01-6P 824982-02-7P 824982-03-8P
824982-04-9P 824982-05-0P 824982-06-1P
824982-10-7P 824982-34-5P 824982-36-7P
824982-37-8P 824982-39-0P 824982-40-3P
824982-41-4P
(preparation of N-phenyl-heterocyclylcarboxylic acid amide derivs. useful for treating pain)
RN 801305-52-2 USPATFULL
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-[4-(1,1-dimethylethyl)phenyl]-3,6-dihydro-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 801305-97-5 USPATFULL
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-(4-chlorophenyl)-3,6-dihydro-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 801305-98-6 USPATFULL
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-(3-fluoro-4-methylphenyl)-3,6-dihydro-3'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 801305-99-7 USPATFULL
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-[4-(1,1-

dimethylethyl)phenyl]-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 801306-00-3 USPATFULL
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-3,6-dihydro-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 801306-02-5 USPATFULL
CN [1(2H),2'-Bipyridine]-4-carboxamide, N-(4-bromophenyl)-3'-chloro-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 801306-05-8 USPATFULL
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-(4-chlorophenyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 801306-07-0 USPATFULL
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-3,6-dihydro-N-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)



RN 801306-09-2 USPATFULL
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-(4-ethylphenyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 801306-12-7 USPATFULL
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-(3-fluoro-4-methylphenyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 824981-93-3 USPATFULL
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-3,6-dihydro-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 824981-94-4 USPATFULL
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-3,6-dihydro-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 824981-95-5 USPATFULL
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3'-chloro-N-(4-fluorophenyl)-3,6-dihydro- (9CI) (CA INDEX NAME)



RN 824982-40-3 USPATFULL
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3,6-dihydro-3'-(trifluoromethyl)-N-[4-[(trifluoromethyl)thio]phenyl]- (9CI) (CA INDEX NAME)



RN 824982-41-4 USPATFULL
CN [1(2H),2'-Bipyridine]-4-carboxamide, 3,6-dihydro-3'-(trifluoromethyl)-N-[4-[(trifluoromethyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 3 OF 6 USPATFULL on STN
ACCESSION NUMBER: 2004:280890 USPATFULL
TITLE: Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
INVENTOR(S): Schwink, Lothar, Stadtallendorf, GERMANY, FEDERAL REPUBLIC OF
Stengelin, Siegfried, Eppstein, GERMANY, FEDERAL REPUBLIC OF
Gossel, Matthias, Hofheim, GERMANY, FEDERAL REPUBLIC OF
Boehme, Thomas, Ruesselsheim, GERMANY, FEDERAL REPUBLIC OF
Hessler, Gerhard, Hofheim, GERMANY, FEDERAL REPUBLIC OF
Stahl, Petra, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
Gretzke, Dirk, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Frankfurt am Main, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

NUMBER	KIND	DATE

PATENT INFORMATION: US 2004220191 A1 20041104
APPLICATION INFO.: US 2004-779853 A1 20040217 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2003-10306250	20030214
	US 2003-488545P	20030718 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ROSS J. OEHLER, AVENTIS PHARMACEUTICALS INC., ROUTE 202-206, MAIL CODE: D303A, BRIDGEWATER, NJ, 08807
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 9357
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to substituted N-aryl heterocycles and to the physiologically tolerated salts and physiologically functional derivatives thereof.

Compounds of the formula I ##STR1##

in which the radicals have the stated meanings, the N-oxides and the physiologically tolerated salts thereof and process for the preparation thereof are described. The compounds are suitable for example as anorectic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **748169-70-2P 748169-74-6P 748169-77-9P**
748175-39-5P
(preparation of N-arylheterocycles as MCH antagonists)

RN 748169-70-2 USPATFULL
CN 4-Piperidinecarboxamide, 1-(5-chloro-2-pyridinyl)-N-[4-[3-(dimethylamino)-1-pyrrolidinyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 748169-74-6 USPATFULL
CN 4-Piperidinecarboxamide, N-[4-[3-(dimethylamino)-1-pyrrolidinyl]phenyl]-1-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 748169-77-9 USPATFULL
CN 4-Piperidinecarboxamide, 1-(5-chloro-2-pyridinyl)-N-[4-[3-(dimethylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 748175-39-5 USPATFULL
CN 4-Piperidinecarboxamide, N-[4-[3-(dimethylamino)-1-pyrrolidinyl]phenyl]-1-[5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 4 OF 6 USPATFULL on STN

ACCESSION NUMBER:	2004:197384 USPATFULL
TITLE:	Vanilloid receptor ligands and their use in treatments
INVENTOR(S):	Balan, Chenera, Thousand Oaks, CA, UNITED STATES Bo, Yunxin, Thousand Oaks, CA, UNITED STATES Dominguez, Celia, Thousand Oaks, CA, UNITED STATES Fotsch, Christopher H., Thousand Oaks, CA, UNITED STATES Gore, Vijay K., Thousand Oaks, CA, UNITED STATES Ma, Vu Van, Simi Valley, CA, UNITED STATES Norman, Mark H., Thousand Oaks, CA, UNITED STATES Ognyanov, Vassil I., Thousand Oaks, CA, UNITED STATES Qian, Yi-Xin, Thousand Oaks, CA, UNITED STATES Wang, Xianghong, Moorpark, CA, UNITED STATES Xi, Ning, Thousand Oaks, CA, UNITED STATES Xu, Shimin, Thousand Oaks, CA, UNITED STATES
PATENT ASSIGNEE(S):	Amgen Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004152690	A1	20040805	
APPLICATION INFO.:	US 2003-688246	A1	20031016	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-419791P	20021017 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	AMGEN INCORPORATED, MAIL STOP 27-4-A, ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA, 91320-1799
NUMBER OF CLAIMS:	14
EXEMPLARY CLAIM:	1
LINE COUNT:	8263

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Therapeutic benzimidazoles and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder

disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, bums, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **683240-63-3P**, N-(2-Amino-4-trifluoromethylphenyl)-1-[1-(3-chloropyridin-2-yl)piperidin-4-yl]formamide **683240-64-4P**, N-(2-Amino-5-trifluoromethylphenyl)-1-[1-(3-chloropyridin-2-yl)piperidin-4-yl]formamide
(intermediate; preparation of benzimidazoles as vanilloid receptor ligands)
RN 683240-63-3 USPATFULL
CN 4-Piperidinecarboxamide, N-[2-amino-4-(trifluoromethyl)phenyl]-1-(3-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 683240-64-4 USPATFULL
CN 4-Piperidinecarboxamide, N-[2-amino-5-(trifluoromethyl)phenyl]-1-(3-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 5 OF 6 USPATFULL on STN
ACCESSION NUMBER: 2003:201609 USPATFULL
TITLE: Novel Cyclic hydroxamic acid as metalloproteinase inhibitors
INVENTOR(S): Xue, Chu-Biao, Hockessin, DE, UNITED STATES
Decicco, Carl P., Kennett Square, PA, UNITED STATES
He, Xiaohua, Hockessin, DE, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003139597	A1	20030724	
	US 6858626	B2	20050222	
APPLICATION INFO.:	US 2002-177235	A1	20020620	(10)

10/618,016

RELATED APPLN. INFO.: Division of Ser. No. US 1999-335086, filed on 17 Jun 1999, GRANTED, Pat. No. US 6429213

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-89557P	19980617 (60)
	US 1999-127599P	19990402 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BRISTOL-MYERS SQUIBB PHARMA COMPANY, PATENT DEPARTMENT, P.O. BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
LINE COUNT: 6318
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present application describes novel cyclic hydroxamic acids of formula I: ##STR1##

or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NR.sup.a, and S(O).sub.p, and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as metalloprotease inhibitors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **252918-46-0P**
(preparation of cyclic hydroxamic acids as metalloproteinase inhibitors)
RN 252918-46-0 USPATFULL
CN 3,4-Piperidinedicarboxamide, N3-hydroxy-N4-[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]-1-(5-nitro-2-pyridinyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 6 OF 6 USPATFULL on STN
ACCESSION NUMBER: 2002:194891 USPATFULL
TITLE: Cyclic hydroxamic acids as metalloproteinase inhibitors
INVENTOR(S): Xue, Chu-Biao, 11 Rivendell Ct., Hockessin, DE, United States 19702
Decicco, Carl P., 102 Indian Springs, Kennett Square,

PA, United States 19711
He, Xiaohua, 12 Old Flint Cir., Hockessin, DE, United States 19707

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6429213	B1	20020806
APPLICATION INFO.:	US 1999-335086		19990617 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-89557P	19980617 (60)
	US 1999-127599P	19990402 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Seaman, D. Margaret
LEGAL REPRESENTATIVE: Vance, David H., Belfield, Jing S.
NUMBER OF CLAIMS: 42
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 4673

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present application de gibes novel cyclic hydroxamic acids of formula I: ##STR1##

or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NR.sup.a, and S(O).sub.p, and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as metalloprotease inhibitors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **252918-46-0P**
(preparation of cyclic hydroxamic acids as metalloproteinase inhibitors)

RN 252918-46-0 USPATFULL

CN 3,4-Piperidinedicarboxamide, N3-hydroxy-N4-[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]-1-(5-nitro-2-pyridinyl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.